Concepedia

David Sanden

DS

5

Publications

566

Citations

5

H-Index

1999

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

David Sanden is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, immunology, and autoimmune disease.

Top concepts

Publications per year

1999–2019

5

Publications

5

SOCS-3 Is Tyrosine Phosphorylated in Response to Interleukin-2 and Suppresses STAT5 Phosphorylation and Lymphocyte Proliferation

S. Cohney, David Sanden, Nicholas A. Cacalano et al. · Molecular and Cellular Biology · 1999 · 264 citations · Full text

, , +19

Tyrosine-phosphorylated SOCS-3 inhibits STAT activation but binds to p120 RasGAP and activates Ras

Nicholas A. Cacalano, David Sanden, James A. Johnston · Nature Cell Biology · 2001 · 209 citations

, , +9

The deubiquitinating enzyme DUB-2 prolongs cytokine-induced signal transducers and activators of transcription activation and suppresses apoptosis following cytokine withdrawal

Thi‐Sau Migone, Martine Humbert, Anne Rascle et al. · Blood · 2001 · 45 citations · Full text

Novel Benzimidazole Inhibitors Bind to a Unique Site in the Kinesin Spindle Protein Motor Domain

Payal R. Sheth, Gerald W. Shipps, Wolfgang Seghezzi et al. · Biochemistry · 2010 · 28 citations · Full text

Evaluation of a TGN1412 analogue using in vitro assays and two immune humanized mouse models

Hangyi Yan, Bhagyashree Bhagwat, David Sanden et al. · Toxicology and Applied Pharmacology · 2019 · 20 citations

, , +10

Rows per page

1–5 of 5